Form 4 for HLSQ Tessera Defense & Homeland Security Inc.

Accepted 2021-07-30 00:00:00 ET · period of report 2021-07-28 · accession 0001213900-21-039435 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2021-07-30	2021-07-28	HLSQ	Greig Russell	Dir	P - Purchase	$4.00	+3,750	3,750	New	+$15.0K
DI	2021-07-30	2021-07-28	HLSQ	Greig Russell	Dir	P - Purchase	—	+2,813	2,813	New	—

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-28	P	A	3,750	$4.00	3,750	I See Footnote	—	—	(F1) The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I. (F3) The common stock and common stock warrant are held by Greig Biotechnology Global Consulting Inc.; Mr. Greig, as the sole director, an officer and the controlling shareholder of Greig Biotechnology Global Consulting Inc., may be deemed to be a beneficial owner of these shares, but Mr. Greig disclaims such beneficial ownership except to the extent of his pecuniary interest therein.
2	Derivative	Common Stock Warrant	2021-07-28	P	A	2,813	—	2,813	I See Footnote	$5.00 · 2022-01-28 to 2027-01-28	2,813 Common Stock	(F1) The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I. (F3) The common stock and common stock warrant are held by Greig Biotechnology Global Consulting Inc.; Mr. Greig, as the sole director, an officer and the controlling shareholder of Greig Biotechnology Global Consulting Inc., may be deemed to be a beneficial owner of these shares, but Mr. Greig disclaims such beneficial ownership except to the extent of his pecuniary interest therein. (F2) The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.